Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5376-5378

  Marcos, Luis A ^a   Camins, Bernard C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; DOXYCYCLINE; TELAVANCIN; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIUM ISOLATION; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; NONHUMAN; PACEMAKER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ENDOCARDITIS; FEMALE; HUMANS; MIDDLE AGED; PACEMAKER, ARTIFICIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 78649688378     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00857-10     Document Type: Article

References (10)

1. Baddour, L. M., W. R. Wilson, A. S. Bayer, et al. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Dis. in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-e434.
2. Bae, I. G., J. J. Federspiel, J. M. Miró, et al. 2009. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J. Infect. Dis. 200:1355-1366.
3. Drees, M., and H. Boucher. 2006. New agents for Staphylococcus aureus endocarditis. Curr. Opin. Infect. Dis. 19:544-550.
4. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155.
5. Howden, B. P., J. K. Davies, P. D. Johnson, T. P. Stinear, and M. L. Grayson. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
6. Julian, K., K. Kosowska-Shick, C. Whitener, et al. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448.
7. Madrigal, A. G., L. Basuino, and H. F. Chambers. 2005. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3163-3165.
8. Mendes, R. E., G. J. Moet, M. J. Janechek, and R. N. Jones. 2010. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:2704-2706.
9. Miro, J. M., C. Garcia-de-la-Maria, Y. Armero, et al. 2007. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2373-2377.
10. Nace, H., and B. Lorber. 2010. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J. Antimicrob. Chemother. 65:1315-1316.